Abiopharma

New Form 6-K - BioNTech SE Filed: 2025-09-08 AccNo: 0001776985-25-000057 Size: 1 MB

New Form 8-K - Verastem, Inc. Filed: 2025-09-08 AccNo: 0001104659-25-088021 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Ocular Therapeutix™ to Host Investor Day on September 30, 2025

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Tonix Pharmaceuticals Presents Clinical Data onTonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

EDAP Receives HIFU Reimbursement for Prostate Cancer in France

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Compugen to Present Research at the Single Cell Genomics 2025 Conference

New Form 8-K - ANI PHARMACEUTICALS INC Filed: 2025-09-08 AccNo: 0001023024-25-000089 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Pfizer Inc. - Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Lillys Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïveCLL/SLL